Every Form 4 that PolyPid Ltd. (PYPD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PYPD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PYPD filings page.
PolyPid Ltd. granted Chief Operating Officer – US Ori Warshavsky a stock option for 46,000 Ordinary Shares with an exercise price of 4.4600 per share. The option vests quarterly from May 11, 2026 through May 11, 2030 and expires on May 11, 2036.
PolyPid Ltd. reported that Chief Financial Officer Jonathan Missulawin received a grant of stock options for 49,000 Ordinary Shares on May 11, 2026. The options have an exercise price of $4.46 per share, an exercise date of August 11, 2026, and expire on May 11, 2036. According to the vesting terms, they vest on a quarterly basis beginning May 11, 2026 until May 11, 2030, leaving him with 49,000 options outstanding.
PolyPid Ltd. granted its Deputy CEO, EVP, RD, CRA, Dalit Fellous Hazan 75,000 stock options on May 11, 2026, with an exercise price of $4.4600 per share for 75,000 Ordinary Shares.
The options vest on a quarterly basis from May 11, 2026 until May 11, 2030 and expire on May 11, 2036; following this grant she holds 75,000 options directly.
PolyPid Ltd. director Barenholz Yechezkel reported a grant of stock options covering 9,132 Ordinary Shares at an exercise price of 4.46 per share. The options vest on a quarterly basis beginning July 15, 2026 until April 15, 2030 and expire on 2036-07-15, leaving him holding 9,132 options directly.
Stein Robert Benjamin reported acquisition or exercise transactions in this Form 4 filing.
PolyPid Ltd. director Robert Benjamin Stein received a grant of 9,132 stock options to purchase Ordinary Shares at $4.46 per share. The options vest on a quarterly basis beginning July 15, 2026 until April 15, 2030 and expire on July 15, 2036. Following this grant, he holds 9,132 options directly.
PolyPid Ltd. director Dror-Darwish Nir received a grant of stock options covering 9,132 Ordinary Shares. The options have an exercise price of $4.46 per share, vest quarterly beginning July 15, 2026 until April 15, 2030, and expire on July 15, 2036. Following this award, he holds options for 9,132 shares, reported as direct ownership. The transaction is categorized as a grant or award acquisition rather than an open-market trade.
PolyPid Ltd. director Joseph BenAmram reported a compensation grant of stock options to acquire 9,132 Ordinary Shares. The options have an exercise price of $4.46 per share and expire on July 15, 2036. They vest on a quarterly basis beginning July 15, 2026 until April 15, 2030, and this award brings his reported stock option holdings to 9,132 options.
PolyPid Ltd. reported that director Itzhak Krinsky received a grant of stock options for 9,132 Ordinary Shares at an exercise price of $4.4600 per share. The options vest on a quarterly basis from July 15, 2026 until April 15, 2030 and expire on July 15, 2036.
PolyPid Ltd. director Story Brooke received a grant of 9,132 stock options to acquire Ordinary Shares at an exercise price of 4.4600 per share. All 9,132 options are held directly, vest on a quarterly basis beginning July 15, 2026 until April 15, 2030, and expire July 15, 2036.
PolyPid Ltd. granted 149,000 stock options to Chief Executive Officer Akselbrad Dikla Czaczkes. The options relate to Ordinary Shares at an exercise price of $4.46 per share, vest quarterly from May 11, 2026 through May 11, 2030, and expire on July 15, 2036.